MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
Atea Pharmaceuticals ROCE Ratio 2011-2026 | AVIR
Annual ROCE Ratio Atea Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -65.67 | -43.97 | -29.57 | -20.4 | 19.49 | -2.01 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.49 | -65.67 | -23.69 |
Quarterly ROCE Ratio Atea Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.39 | -37.07 | -35.57 | -31.8 | -38.81 | -37.71 | -33.71 | -19.58 | -22.04 | -17.48 | -16.52 | -13.55 | -17.36 | -18.71 | -12.37 | 2.87 | -0.35 | 0.25 | -3.03 | -5.78 | 1.82 | 12.64 | 14.47 | 7.6 | 7.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.47 | -43.39 | -14.3 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.94 | 2.45 % | $ 1.03 B |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.73 | 3.51 % | $ 3.77 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 1.98 | 3.4 % | $ 412 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.46 | 5.58 % | $ 157 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-631.87 | $ 24.14 | -0.29 % | $ 314 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Heron Therapeutics
HRTX
|
-17.71 | $ 1.23 | 2.94 % | $ 205 M | USA |
 |
ImmuCell Corporation
ICCC
|
4.28 | $ 8.22 | -1.56 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
InflaRx N.V.
IFRX
|
-24.77 | $ 1.56 | 5.07 % | $ 152 M | Germany |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Innate Pharma S.A.
IPHA
|
0.41 | $ 1.4 | 1.09 % | $ 235 M | France |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Inventiva S.A.
IVA
|
-23.77 | $ 5.11 | -0.78 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
245.65 | $ 0.33 | -13.82 % | $ 770 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 102.65 | -2.66 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4132.68 | $ 20.05 | 2.11 % | $ 1.08 B | Britain |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.14 | 1.59 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.65 | 1.68 % | $ 3.01 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.44 | -0.35 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 230.83 | -0.19 % | $ 4.22 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.92 | 0.24 % | $ 4.81 M | Israel |
 |
Eli Lilly and Company
LLY
|
21.04 | $ 881.74 | -0.28 % | $ 791 B | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |